Abstract:ID 18908 Poster Board 186 Pregnane X receptor (PXR, NR1I2), a ligand-activated transcription factor, is relatively abundant in liver and intestine. Previous studies have demonstrated that PXR activation inhibits liver fibrosis, but the specific mechanisms still remain unclear. Leukocyte cell-derived chemotaxin 2 (LECT2), a downstream target of β-catenin/ T cell-specific factor 4 (TCF4) signaling, is a small-molecule protein secreted by hepatocytes. Recent study illustrated that LECT2 produced by hepatocytes participated in the progression of hepatic fibrosis by regulating angiogenesis. In the current study, we aimed to investigate whether PXR activation attenuate liver fibrosis by inhibiting LECT2 and explore its impact on β-catenin/TCF4 signaling. Additionally, we also aimed to unveil the critical role of β-catenin/TCF4-LECT2 axis in liver fibrosis and demonstrate whether PXR activation alleviates hepatic fibrosis via inhibiting β-catenin/TCF4-LECT2 axis. In the current study, carbon tetrachloride (CCl4) was used to induce liver fibrosis in C57BL/6 mice. The results showed that mouse PXR agonist pregnenolone-16α-carbonitrile (PCN) significantly attenuated hepatic fibrosis by suppressing the expression of α-smooth muscle actin (α-SMA), Collagen ? and platelet endothelial cell adhesion molecule-1 (CD31). Lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1) and CD31 staining indicated that PXR activation inhibited sinusoids capillarization and central angiogenesis. Besides, immunohistochemical (IHC) staining and western blot analysis indicated that LECT2 and nuclear β-catenin were significantly downregulated after PXR activation, while total β-catenin and TCF4 didn’t alter significantly. Furthermore, reporter gene assay was performed and suggested that PXR activation inhibited the transcriptional activation of LECT2 by β-catenin/TCF4. PXR activation disrupted the interaction between β-catenin and TCF4. Co-Immunoprecipitation (Co-IP) assays further indicated that PXR potentially interacted with β-catenin and TCF4 simultaneously. Moreover, to clarify whether disrupting β-catenin/TCF4 interaction alleviated liver fibrosis, β-catenin/TCF4 inhibitor LF3 was used to evaluate its effect on liver fibrosis. The results showed the inhibition of β-catenin/TCF4 interaction decreased the expression level of LECT2 and alleviated liver fibrosis. In addition, AAV-Lect2 mice was used and we found that PXR activation failed to protect liver from fibrosis in AAV-Lect2 mice, which further confirmed that PXR attenuated hepatic fibrosis by inhibiting LECT2. Finally, we clarified that long-term treatment of PCN had no risk for carcinogenesis or promoting tumor formation induced by diethylnitrosamine (DEN), indicating the safety of long-term activation of PXR. Taken together, this study demonstrated a new mechanism that PXR attenuated liver fibrosis by disrupting β-catenin/TCF4 interaction and suppressing the expression level of LECT2. The crosstalk between PXR and β-catenin/TCF4 signaling was also clarified. These findings provide new evidence and theoretical basis for PXR as potential drug target for liver fibrosis.

Raspberry Ketone Attenuates Hepatic Fibrogenesis and Inflammation via Regulating the Crosstalk of FXR and PGC-1α Signaling

Extraction of raspberry ketone from red raspberry and its intervention in the non-alcoholic fatty liver disease

Raspberry ketone protects rats fed high-fat diets against nonalcoholic steatohepatitis

Antioxidant properties of red raspberry extract alleviate hepatic fibrosis via inducing apoptosis and transdifferentiation of activated hepatic stellate cells

Fluorofenidone Attenuates Hepatic Fibrosis By Suppressing The Proliferation And Activation Of Hepatic Stellate Cells

The Antihepatic Fibrotic Effects of Fluorofenidone Via Mapk Signalling Pathways

Ginsenoside Rd, a natural production for attenuating fibrogenesis and inflammation in hepatic fibrosis by regulating the ERRα-mediated P2X7r pathway

Antifibrotic Effects of Kangxian Ruangan Capsule on Rats with Nonalcoholic Fatty Liver Fibrosis and Hepatic Stellate Cells through Regulation of TGF-β and TLR4 Signaling Pathways

Fucoxanthin Alleviates Renal Fibrosis in Experimental Diabetic Nephropathy by Regulating P62/keap1/nrf2 Signaling and Improving Mitochondrial Damage

20S-Protopanaxatriol Ameliorates Hepatic Fibrosis, Potentially Involving FXR-Mediated Inflammatory Signaling Cascades

Targeting antioxidant factor Nrf2 by raffinose ameliorates lipid dysmetabolism-induced pyroptosis, inflammation and fibrosis in NAFLD

Astilbin alleviates hepatic fibrosis through PXR-PINK1/Parkin pathway: A new strategy by regulating hepatic stellate cells-macrophage crosstalk

Ketogenic Diet Alleviates Renal Fibrosis in Mice by Enhancing Fatty Acid Oxidation Through the Free Fatty Acid Receptor 3 Pathway

Ameliorative effects of Compound K and ginsenoside Rh1 on non-alcoholic fatty liver disease in rats

PXR Activation Attenuates Liver Fibrosis by Down-Regulating LECT2 and Disrupting -Catenin/tcf4 Interaction

Raspberry Ketone Reduced Lipid Accumulation in 3T3-L1 Cells and Ovariectomy-Induced Obesity in Wistar Rats by Regulating Autophagy Mechanisms

Kaempferol attenuates carbon tetrachloride (CCl4)-induced hepatic fibrosis by promoting ASIC1a degradation and suppression of the ASIC1a-mediated ERS

Resveratrol Alleviates Hepatic Fibrosis in Associated with Decreased Endoplasmic Reticulum Stress-Mediated Apoptosis and Inflammation

Shen-Shuai-II-Recipe inhibits tubular inflammation by PPARα-mediated fatty acid oxidation to attenuate fibroblast activation in fibrotic kidneys

Farnesoid X Receptor Activation Protects Against Renal Fibrosis Via Modulation of Β-Catenin Signaling.

Ginsenoside Compound K Restrains Hepatic Fibrotic Response by Dual-Inhibition of GLS1 and LDHA